343 related articles for article (PubMed ID: 36045725)
1. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
Shao T; Ren Y; Zhao M; Tang W
Front Public Health; 2022; 10():912921. PubMed ID: 36045725
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
Front Public Health; 2021; 9():743558. PubMed ID: 34957008
[No Abstract] [Full Text] [Related]
3. Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China.
Zhu C; Xing XX; Wu B; Liang G; Han G; Lin CX; Fang HM
Front Pharmacol; 2021; 12():735536. PubMed ID: 35002693
[No Abstract] [Full Text] [Related]
4. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.
Dai H; Wang W; Fan X; Chen Y
Front Med (Lausanne); 2023; 10():1122731. PubMed ID: 36865055
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer.
Liang X; Chen X; Li H; Li Y
Immunotherapy; 2023 Oct; 15(14):1133-1142. PubMed ID: 37492009
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma.
Gong J; Shang J; Su D; Qian X; Liu G; Sun Z
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):709-717. PubMed ID: 37190977
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
Rui M; Fei Z; Wang Y; Zhang X; Ma A; Sun H; Li H
J Med Econ; 2022; 25(1):618-629. PubMed ID: 35475459
[TBL] [Abstract][Full Text] [Related]
10. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
Huo G; Liu W; Kang S; Chen P
Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
[No Abstract] [Full Text] [Related]
11. Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis.
Chen X; Zhao M; Tian L
Front Pharmacol; 2023; 14():1119906. PubMed ID: 37021058
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
16. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
17. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Ren S; Chen J; Xu X; Jiang T; Cheng Y; Chen G; Pan Y; Fang Y; Wang Q; Huang Y; Yao W; Wang R; Li X; Zhang W; Zhang Y; Hu S; Guo R; Shi J; Wang Z; Cao P; Wang D; Fang J; Luo H; Geng Y; Xing C; Lv D; Zhang Y; Yu J; Cang S; Yang Z; Shi W; Zou J; Zhou C;
J Thorac Oncol; 2022 Apr; 17(4):544-557. PubMed ID: 34923163
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma.
Shao T; Zhao M; Tang W
Front Oncol; 2022; 12():953671. PubMed ID: 36561521
[TBL] [Abstract][Full Text] [Related]
20. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.
Chen T; Xie R; Zhao Q; Cai H; Yang L
Front Oncol; 2022; 12():746526. PubMed ID: 35936702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]